Journal Scans
Administration of Bortezomib Before and After Autologous Stem-Cell Transplantation Improves Outcome in Multiple Myeloma Patients With Deletion 17p
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
K Neben, HM Lokhorst, A Jauch, H Goldschmidt, et al
Yes
20111108
2011 Dec 8
Blood
Administration of Bortezomib Before and After Autologous Stem-Cell Transplantation Improves Outcome in Multiple Myeloma Patients With Deletion 17p
Blood. 2011 Dec 8;[Epub Ahead of Print], K Neben, HM Lokhorst, A Jauch, H Goldschmidt, et al
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
In patients with Multiple Myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. Here we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/GMMG-HD4 trial. Because of the two-arm design of the study, we were able to analyze the effect of a bortezomib-based treatment before and after autologous stem-cell transplantation (arm B) in comparison to standard treatment...
